Chordia Therapeutics 190A.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 190A.T. It has been listed since 14 June 2024. In the fiscal year to 31 August 2023, it reported revenue of ¥2.50bn and net income of ¥223.3m. At that date it held total assets of ¥4.91bn and shareholders' equity of ¥4.50bn.

Chordia Therapeutics, Inc. engages in the research and development of novel therapies for cancers. The company is headquartered in Fujisawa-Shi, Kanagawa-Ken. The company went IPO on 2024-06-14. The firm's main business is the research and development of small molecule breakthrough drugs (first-in-class) with novel actions in the field of oncology, where there is a high unmet medical need. The firm concentrates on management and research operations (exploratory, preclinical, and clinical research), particularly in the discovery, evaluation, optimization, and clinical testing of candidate compounds, and outsources basic research, active pharmaceutical ingredient and drug product manufacturing, distribution, and sales to its various external partners to advance its business.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Hiroshi MiyakeChief Executive Officer, Co-Founder, Representative Director, since 2022
• Mr. Daisuke MorishitaCo-Founder, Chief Scientific Officer
• Mr. Kentaro KumeChief Financial Officer
• Ms. Ayuko HashimotoIndependent Director
• Mr. Kosuke IshiiIndependent Director
• Mr. Akihiko ShimauchiIndependent Director
• Mr. Nishikata YukariIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.